InferVision Appoints Renowned AI and Genomics Scientist Dr. Huiyuan Xiong as Chief Scientist to Integrate Genomic Data and Expand Globally

Dr. Huiyuan Xiong, a world-renowned expert in deep learning and co-founder of Deep Genomics, a leading North American company at the intersection of genomics and artificial intelligence, will join Infervision as its Chief Scientist. Dr. Xiong has published numerous papers in prestigious international academic journals, including the Science and Nature series. Upon joining Infervision,Xiong Huiyuan will be responsible for the research and development of the company’s radiomics-related products.。

Xiong Huiyuan

Radiomics is an emerging frontier discipline based on quantitative imaging, feature extraction, image analysis, and model construction. It leverages multiple imaging features to intuitively and quantitatively describe the morphological and pathological characteristics of tumors in clinical practice, thereby providing robust imaging support for clinical decision-making.

There are currently four main types of clinical applications:

1. Application of efficacy evaluation and prediction for radiotherapy and chemotherapy;

2. Tumor Grading Applications. Tumor grading holds significant clinical importance, as it informs clinical diagnostic and therapeutic decision-making and the formulation of imaging-guided treatment plans;

3. Application for Differentiating Between Benign and Malignant TumorsRadiomics features can differentiate between benign and malignant tumors in many clinical applications, thereby guiding clinical decision-making; 

4. Applications of Cancer Genetics. ScientistsStudies have found a strong correlation between tumor pathology and tumor genetics. Research in tumor genetics can provide a biological basis for tumor diagnosis. Radiomics serves as an excellent integration of pathology and genomics, making it an important tool for research in tumor genetics.。

As an emerging frontier discipline, radiomics closely integrates imaging, pathological, and genomic information, leveraging engineering methodologies to provide a comprehensive suite of solutions for clinical decision-making and scientific research. Beyond its significant role in the aforementioned applications, radiomics is poised to play an increasingly vital part in other clinical areas in the future.

Who is Xiong Huiyuan, and why does Infervision place such high importance on him? Let’s take a look at his resume.

Xiong Huiyuan graduated from the Department of Computer Engineering at the University of Toronto, a key birthplace of deep learning. Since 2009, his primary research focus has been on unlocking the vast potential of machine learning to enhance human health and medical care. He published his first paper in Science at the age of 26, and again appeared as the first author in Science at 29. His academic work has also been featured multiple times in prestigious international journals, including the Nature portfolio.

The deep learning model co-developed by Xiong Huiyuan is a global leader, with applications spanning medical image processing, genomics, molecular biology, and new drug research and development.Featured by multiple media outlets, including The New York Times, The Washington Post, Wired, Scientific American, Quanta, CBC, and the National Post.

In 2015, Huiyuan Xiong co-founded the renowned biotech startup Deep Genomics with his doctoral supervisor, Brendan Frey, a Fellow of the Royal Society of Canada, and others.The company is dedicated to leveraging deep learning models to study genetic variations and develop novel gene-based therapeutics, while employing machine learning to construct predictive models that assess the impact of genomic mutations on cells and the human body.. Deep Genomics was listed by CB Insights in 2017 as one of the 100 most promising artificial intelligence companies worldwide.

During his doctoral studies at the University of Toronto, Dr. Huiyuan Xiong developed a strong bond with his Ph.D. supervisor, Brendan Frey.

Brendan Frey is a co-founder of the Machine Learning Group at the University of Toronto, and isMachine learning and genomic researcher,He is known for his research on factor graphs, wake-sleep algorithms in deep learning, and the application of machine learning techniques in simulating genomic biology and understanding genetic diseases. He has also developedIdentification of Genetic Determinants of Diseasea new calculation method.

Both Brendan Frey and Dr. Yann LeCun, Facebook’s Director of AI, studied under Geoffrey Hinton, the “godfather of deep learning.”

Since 2009, Dr. Xiong Huiyuan has also conducted research under the supervision of Geoffrey Hinton, and his papers have been praised and cited by Professor Hinton on multiple occasions.

Since leaving China in 2002 to pursue his career abroad, Xiong Huiyuan has never returned to work in the country. Over the past fifteen years, he has closely monitored China’s rapid economic and technological development, as well as its vast market demand. Xiong HuiyuanSpecialtiesIt is machine learning (currently, universities only offer majors in machine learning, with deep learning being a course within this major). There is a key advantage in the combination of Infervision's applications and his professional expertise.It involves in-depth collaboration with hospitals.。

Xiong Huiyuan stated that the field of machine learning has developed rapidly in recent years. In many applications, as long as there is sufficient data, even very complex problems can be addressed by building predictive models, enabling computer software to perform at a level comparable to or even surpassing that of humans. With a large volume of patient data samples in China, Infervision holds a significant advantage in clinical data collection, leveraging its collaborative partnerships with numerous Grade IIIA hospitals.

“I find three aspects of Pushing Medical Technology particularly appealing to me.First, Infervision holds significant potential; the scarcity of medical resources in China has created a favorable opportunity for machine learning to aid in patient care.Second, Infervision’s data samples are highly diverse, facilitating model optimization to create a virtuous cycle;Third“There are vast uncharted territories in healthcare related to medical imaging and artificial intelligence. By leveraging Infervision’s existing breakthroughs, many new directions for expansion have emerged. Furthermore, I deeply admire the Infervision team’s execution capabilities and their down-to-earth spirit. I look forward to working with them,” said Xiong Huiyuan.。

As a medical artificial intelligence company, Infervision’s current products apply deep learning technology toAI-Assisted Medical Imaging ScreeningProvide fast and accurate solutions.

Xiong Huiyuan’s joining will inject fresh blood into Infervision, as the company expands in both business breadth and market reach. Xiong Huiyuan is the co-founder of the biotech startup Deep Genomics, and hasIn-depth Research in the Field of Artificial Intelligence for Genetic Science. As Infervision’s dataset continues to expand, the rapid advancement of its recognition tool models has driven the expansion of radiomics technology. Currently, the company’s product development is no longer limited to the analysis of medical images.

Infervision’s introduction of an AI genetics expert also reflects the recognition that disease diagnosis and treatment cannot be addressed by imaging alone; rather, it requires the integration of multi-modal information, including genomics, imaging, and pathology. The addition of Xiong Huiyuan will accelerate Infervision’s expansion plans to develop deep learning models in genomics and other fields.At the same time, this makes Infervision the second Chinese technology company, after BGI Genomics in Shenzhen, to possess the capability for scientific publications in the *Science* and *Nature* journal families.

Chen Kuan, Founder and CEO of Infervision, delivered a speech as the sole representative of Chinese medical AI companies invited to the GTC AI Summit in Silicon Valley. Covered by Forbes and other major international media outlets, this exposure significantly elevated Infervision’s global visibility and influence, laying a solid foundation for its expansion onto the international stage.

Recently,Infervision’s Japan office has been officially established in Chiyoda Ward, the political and economic heart of Tokyo, a key market for medical imaging in the Asia-Pacific region.This will be an important milestone for Infervision as it seeks global partners and moves toward internationalization. Dr. Xiong Huiyuan’s many years of work experience in Canada have endowed him with a broad international perspective, which will also play a key role in helping Infervision expand into overseas markets.